Zydus Lifesciences along with its Q4 results today approved a share buyback worth up to ₹1,100 crore at a price of ₹1,150 per equity share, representing a premium of nearly 12.7% over the current market price of ₹1,020.
The company said its board approved the repurchase of up to 95,65,217 fully paid-up equity shares of face value ₹1 each through the tender offer route. The proposed buyback represents up to 0.95% of the total paid-up equity share capital of the company.
According to the exchange filing, the buyback size of ₹1,100 crore represents 15.6% and 3.84% of the aggregate of the company’s standalone and consolidated paid-up equity share capital and free reserves respectively, based on audited financial statements as of March 31, 2026.
The company has fixed May 29, 2026, as the record date for determining shareholder eligibility for participation in the buyback offer.
The buyback announcement came alongside the company’s March quarter earnings, where Zydus Lifesciences reported consolidated net profit of ₹1,272.5 crore in Q4 FY26, compared to ₹1,170.9 crore in the corresponding quarter last year, marking a growth of 8.7% year-on-year.
Revenue from operations rose 16.2% YoY to ₹7,587 crore during the quarter from ₹6,527.9 crore in Q4 FY25.
Operationally, EBITDA stood at ₹2,554 crore in Q4 FY26 compared to ₹2,125.5 crore in the year-ago period, while EBITDA margin improved to 33.7% from 32.6%.
Profit before tax and share of profit of joint ventures stood at ₹1,659.7 crore during the quarter, while earnings per share (EPS) came in at ₹12.65 versus ₹11.64 in Q4 FY25.
The company said the buyback will be undertaken through the tender offer route in accordance with SEBI Buyback Regulations and the Companies Act, 2013. It also noted that the board or buyback committee may revise the buyback price and reduce the number of shares proposed to be bought back, provided there is no change in the overall buyback size.